The CXCR4 antagonist AMD3100 is progressively replacing cyclophosphamide (CYP) as adjuvant to granulocyte colonystimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSC) for autologous transplants in patients who failed prior mobilization with G-CSF alone. It has recently emerged that G-CSF mediates HSC mobilization and inhibits bone formation via specific bone marrow (BM) macrophages. We compared the effect of these three mobilizing agents on BM macrophages, bone formation, osteoblasts, HSC niches and HSC reconstitution potential. Both G-CSF and CYP suppressed niche-supportive macrophages and osteoblasts, and inhibited expression of endosteal cytokines resulting in major impairment of HSC reconstitution potential remaining in the mobilized BM. In sharp contrast, although AMD3100 was effective at mobilizing HSC, it did not suppress osteoblasts, endosteal cytokine expression or reconstitution potential of HSC remaining in the mobilized BM.
INTRODUCTION
Granulocyte colony-stimulating factor (G-CSF) has been routinely used to therapeutically mobilize hematopoietic stem cells (HSC) to the bloodstream for transplantation for over two decades. 1 In most healthy donors, G-CSF induces mobilization of sufficient HSC (typically 42 Â 10 6 CD34 þ cells/kg) to ensure a safe transplantation in allogenic recipients. However, a high proportion of cancer patients with prior repeated high dose-chemotherapy cycles fail to mobilize sufficient HSC numbers in response to G-CSF to enable subsequent autologous transplantation. 2 Conditioning with chemotherapy, particularly with the alkylating agent cyclophosphamide (CYP), before G-CSF infusion increases the mobilizing response thereby enabling some poor mobilizers to reach the minimum threshold of 2 Â 10 6 CD34 þ HSPC/kg. However, the unpredictability of the kinetics and extent of mobilization renders this method difficult to implement. 3 More recently AMD3100 (Plerixafor), a small molecule antagonist of the CXCR4 receptor for the chemokine CXCL12, has proven useful to boost mobilization in response to G-CSF. The combination of G-CSF with AMD3100 enables a much larger proportion of non-Hodgkin's lymphoma and multiple myeloma patients who previously failed to mobilize sufficiently with G-CSF alone, to successfully mobilize and proceed with an autologous transplantation. 4, 5 Ten years ago, the first studies revealing the mechanisms of HSC mobilization in response to G-CSF and cytotoxic drugs such as CYP were conducted in humans, primates and mice. 6 --9 These studies showed release of active proteases in the bone marrow (BM) in response to G-CSF or CYP. These proteases can cleave and inactivate many proteins that anchor HSC within the BM stroma, suggesting their involvement in initiating HSC mobilization. However, the physiological role of this mechanism remains uncertain as some inbred mouse strains (particularly C57BL/6) release only small amounts of proteases in response to G-CSF. Furthermore, genetically modified C57BL/6 mice lacking some of these proteases mobilize normally in response to G-CSF. 10 In the past 5 years, it has emerged that G-CSF mobilizes in part by (1) blocking proliferation and osteogenic differentiation of mesenchymal stem cells (MSC), 11 (2) inducing osteoblast apoptosis 12 and (3) blocking bone formation. 13, 14 This results in a dramatic reduction in the expression of chemokines and cytokines necessary to maintain and retain HSC in their endosteal and perivascular niches such as CXCL12, kit ligand (KL) and angiopoietin-1. 11, 13, 14 Once these endosteal niches are shutdown, HSC mobilization is initiated and possibly further amplified by protease-dependant mechanisms 13 involving neutrophil proteases, 15 CD26, 16 activation of the complement cascade 17 --19 and the thrombolytic pathway. 20 It has recently been reported that specific populations of BM macrophages are necessary to maintain the function of HSC niches in the BM and for the mobilizing effect of G-CSF 13, 21, 22 in particular osteoblast-supportive endosteal phagocytic macrophages called osteomacs 13, 23 and CD11b þ F4/80 þ Ly-6G þ phagocytic macrophages expressing CD169, which are in close association with MSC. 13, 21 Whether these two macrophage populations are distinct according to niche location or functionally overlap remains unknown. G-CSF depletes both these endosteal and BM macrophages in vivo 13, 21, 22 and macrophage depletion transiently inhibits niche function with loss of endosteal osteoblasts, arrest in bone formation and HSC mobilization 13, 21, 22 A single injection of CYP is also sufficient to elicit robust HSC mobilization. In BALB/c mice, CYP increases the release of neutrophil proteases in the BM, with cleavage of VCAM-1 (ref. 7) and decreased CXCL12 concentration 6 in the BM, similar to a 4-day course of G-CSF administration. However, whether CYP shuts down HSC niches in mouse strains such as C57BL/6 with low protease release has not been investigated. AMD3100 has been reported to mobilize HSC by directly antagonizing the CXCR4-mediated sensing of the CXCL12 chemotactic gradient in the BM that retains HSPC within this tissue, 24, 25 and by promoting the release of CXCL12 from BM stromal cells into the circulation, thereby disrupting the CXCL12 gradient that retains HSC within the BM. 26 These latter findings suggest that AMD3100 may also alter HSC niches.
The effect of G-CSF on osteoblasts, HSC niches and BM macrophages has recently been reported, 12, 13, 21, 22 however, it is not known whether CYP and AMD3100 have similar effects. As AMD3100 is progressively replacing CYP as adjuvant to G-CSF to mobilize HSC in lymphoma and multiple myeloma patients who previously failed to mobilize in response to G-CSF alone, 2 we compared the effect of these three mobilizing agents on BM macrophages, bone formation, osteoblasts and HSC niche function.
MATERIALS AND METHODS

Mobilization and tissue harvesting
All experiments were performed on 12 --16 week-old male C57BL/6 mice. Recombinant human G-CSF (Amgen, Thousand Oaks, CA, USA) was injected twice daily subcutaneously at 125 mg/kg per injection for up to 6 consecutive days. Control mice were injected with an equivalent volume of saline. CYP-treated mice were injected intraperitoneally with a single dose of 200 mg/kg CYP diluted in saline.
AMD3100 octohydrochloride (Tocris Bioscience, Bristol, UK) was injected intraperitoneally as a single 16 mg/kg dose corresponding to 10 mg/kg of AMD3100 base. Tissues were harvested 1 h after AMD3100 administration. In other experiments, AMD3100 was administered continuously at 200 mg/day by subcutaneously implanted osmotic pumps (ALZET, Cupertino, CA, USA) for 6 days.
At specified time-points, mice were anesthetized with isofluorane and 1 ml of blood collected into heparinized tubes before exsanguinations by cardiac puncture. For flow cytometry analyses, red cells were lysed from blood samples as previously described. 8 Spleens were harvested, weighed, dissociated in phosphate-buffered saline (PBS) with 2% fetal calf serum (FCS). Cells and RNA from the central region of the BM and RNA from the endosteum were isolated from femurs as previously described. 27 For histomorphometric studies, tibias were fixed in ice cold PBS containing 4% paraformaldehyde, rotated overnight at 4 1C and transferred into 70% ethanol until embedding in methacrylate resin as described. 28 For immunohistology, tibias were fixed similarly for 24 h and then decalcified at 4 1C for 2 weeks with 14% EDTA before embedding in paraffin.
Cell counts and colony assays
For myeloid colony assays, 10 ml whole blood or leukocyte suspension from BM or spleen were deposited in 35 mm petri dishes and covered with 1 ml IMDM supplemented with 16% methylcellulose (high viscosity Methocell MC, Fluka, Sigma-Aldrich, St Louis, MO, USA) and 35% FCS. Optimal concentrations of mouse IL-3, IL-6 and soluble KL were added as conditioned media from stably transfected BHK cell lines. Colonies were counted after 10 days culture.
Quantitative real-time RT-PCR (RT-qPCR) RNA was precipitated, DNase treated and reverse transcribed using random hexamers. qRT-PCR with SYBR green or using Taqman probes (labeled 5 0 with 6-carboxyfluorescein (FAM) and 3 0 with blackhole quencher-1 (BHQ-1)). Oligonucleotide sequences are shown in Table 1 . Primers were designed to cross intron --exon boundaries to not amplify genomic DNA. RNA levels were standardized by parallel RT-qPCR using primers to the house keeping gene b2-microglobulin. A control PCR from each sample before reverse transcription was performed to confirm absence of genomic DNA detection.
Measurement of bone formation and mineral apposition
Mice were injected with CYP or saline on day 0. Calcein was then injected intraperitoneally at 20 mg/kg on days 1, 7, 13 and 19. Mice were killed on day 21. Five mm sections of the proximal tibiae were stained with toluidine blue and histomorphometry carried out in the trabecular bone of the secondary spongiosa according to standard procedures using the Osteomeasure system (OsteoMetrics Inc., Decatur, GA, USA). 28 The measured parameters were the percentage of endosteal bone surface covered by osteoblasts (ObS/BS) or by osteoid (OS/BS). For mineral appositional rates, sections remained unstained and fluorochromes were visualized by epifluorescence microscopy as previously described. 28 
Immunohistochemistry
Sections were deparaffinized and rehydrated with xylene and decreasing ethanol baths and washed in Tris-buffered saline. Immunohistochemistry was used to examine expression of F4/80 (rat anti-mouse F4/80, clone CI:A3-1, AbD Serotec, Oxford, UK) and osteocalcin (rabbit anti-mouse osteocalcin, Alexis Biochemicals, San Diego, CA, USA) as previously described. 13, 23 Flow cytometry
Following flushing with PBS containing 2% FCS, central BM cells were pelleted at 400 g for 5 min at 4 1C and resuspended in CD16/CD32 hybridoma 2.4G2 supernatant to block IgGFc receptors. Mature myeloid cells were stained with CD11b-PECY7, anti-LY-6G-PE (clone 1A8) and anti-F4/80-AlexaFluor647 (clone CI:A3-1).
In long-term competitive repopulation assays, donor CD45.32 chimerism was measured in myeloid, B-and T lymphoid lineages in blood samples after red cell lysis using the following combination of antibodies: CD11b-Pacific Blue, CD3e-FITC, B220-APCCY7, CD45.1-PE and CD45.2-APC.
Long-term competitive repopulation assays
The content of mobilized BM samples in competitive repopulating HSC was determined in competitive repopulation assays. Groups of four donor C57BL/6 CD45.2 þ male mice were injected twice daily with saline or with 125 mg/kg rhuG-CSF for 5 days. In another experiment, groups of four donor Table 1 . Primers and probes used in RT-qPCR analyses
C57BL/6 mice were injected once with saline or once with 200 mg/kg CYP or once with 10 mg/kg AMD3100. Groups of 10 recipient congenic B6.SJL CD45.1 þ mice were lethally irradiated with 11.0 Gy in two split doses 4 h apart the day before BM harvest from donor-mobilized mice.
On transplantation day, one femur per donor mouse was gently crushed in PBS þ 2% NCS with a mortar and pestle; BM cells from all mice within each treatment group (5 days saline, 5 days G-CSF, single saline, 6 days after CYP or 1 h after AMD3100) were pooled. In all, 200 000 BM cell aliquots were taken from this pool and mixed with 200 000 competitive whole BM cells from untreated B6.SJL CD45.1 þ in a total volume of 200 ml, and injected retro-orbitally into each lethally irradiated recipient. Recipients were maintained with antibiotics for the first 3 weeks posttransplant and tail bled 16 weeks post-transplant to determine CD45. 2 
Statistics
Significance levels were calculated using the Student's t-test for colony assays, flow cytometry analyses and qRT-PCR. One-way ANOVA followed by Fisher's PLSD post-hoc test was used for histomorphometric measurements. Non-parametric Mann --Whitney test was used to determine differences in chimerism in long-term competitive repopulation assays.
RESULTS
Effect of G-CSF, CYP and AMD3100 on osteoblasts and bone formation in vivo
Skeletally mature mice were mobilized with either bi-daily injections of G-CSF for 6 days, a single injection of CYP or AMD3100. Mobilization of colony-forming cells to the peripheral blood in response to G-CSF was detectable at day 2 and plateaued between days 4 --6 (Figure 1a) . During G-CSF treatment, as previously reported, 13 cancellous bone surfaces lined with active osteoblasts (ObS/BS) and newly formed bone matrix (osteoid, OS/BS) all decreased as early as 24 h after commencement of the treatment, by 16 to 18-fold at the peak of mobilization and rebounded 4 days after cessation of G-CSF administration to levels 2-fold above baseline (Figure 1b) . This was observed on cortical and trabecular endosteal surfaces in Goldner's trichrome stained sections (Figures 1d and e) where osteoid stains pink and bone greenish-blue.
Unlike G-CSF, the mobilizing response to CYP was biphasic with a myeloablation occurring within the first 3 days following CYP administration. BM cellularity was reduced to 5 --15% of initial steady-state levels 7 and colony-forming cells were not detected in the blood. In a second phase, mobilization peaked during the rebound of medullar hematopoiesis between days 6 --8. At myeloablation on day 3, preceding HSPC mobilization, ObS/BS and OS/BS were double that of baseline (Figure 1b ). At days 6 and 8, when hematopoietic recovery occurs and HSPC are mobilized into the blood, osteoblasts were undetectable and osteoid surface was reduced three to fivefold on trabecular bone surfaces. Surprisingly, despite the loss of osteoblasts, Goldner's trichrome staining (Figure 1d ) confirmed that osteoid remained transiently on trabecular bone surfaces. This could be the result of increased bone formation at day 3. Of note, osteoid in the absence of osteoblasts was not observed in G-CSF-mobilized mice (Figures 1d  and e) . Curiously, we also noted that while osteoblasts had disappeared from the osteoid on trabecular bone surfaces in the metaphysis between days 6 --10 following CYP injection, flattened osteoblasts or bone lining cells still covered osteoid on endocortical bone surface of tibial diaphysis at these time-points.
In order to further evaluate how bone formation was affected by CYP, we performed dynamic histomorphometry on CYP-treated mice by injecting calcein, a fluorescent Ca 2 þ chelator. Calcein was injected four times every 6 days following a single CYP injection: once before mobilization commenced (day 1 post-CYP), one at the peak of mobilization (day 7) and twice during the recovery phase (days 13 and 19) . This was carried out to track changes in bone formation during mobilization and recovery. The percentage of metaphyseal trabecular bone areas covered by quadruple, triple, double or single lines of calcein was measured (Figure 2) . In this experiment, surfaces of continuous bone formation over the 21-day experimental period were covered by four continuous lines of calcein. In untreated, skeletally mature 14-week old mice, these surfaces made up 5.6 ± 2.0% of the total trabecular surface, while 40% of the trabecular surfaces were not active sites of bone formation over the course of the experiment (unlabeled). In CYPmobilized mice, areas covered by four lines of calcein were observed at only 0.6% and in only one animal. Areas covered by three lines of calcein decreased 3.3-fold. Conversely areas covered by a single line of calcein, indicating surfaces on which bone formation only occurred briefly during the 21 day time-course, doubled from 18.8 ± 4.5 to 34.4 ± 4.3%. Taken together these data show that CYP, similar to G-CSF, 13 strongly reduces trabecular bone formation and mineralization.
A single injection of 10 mg/kg AMD3100 rapidly and transiently mobilizes HSC with a peak at 1 h in mice. 24 At this peak, the number of circulating colony-forming cells increased 16-fold ( Figure 1a) . Bone histomorphometry revealed that unlike G-CSF or CYP, AMD3100 did not alter osteoblasts or osteoid surfaces on trabecular or endocortical bone of the metaphysis (Figures 1 b --e) .
Histomorphometric measurements of osteoblasts were confirmed by RT-qPCR on osteoblast-specific osteocalcin at the endosteum (Figure 1c) . At peak of mobilization with G-CSF or CYP, osteocalcin mRNA abundance was reduced 30-fold and 100-fold, respectively. In sharp contrast, levels of osteocalcin mRNA at the endosteum were not significantly altered 1 h after AMD3100 administration (Figure 1) . Similarly, a 6-day continuous AMD3100 infusion by osmotic did not alter osteoblast, osteoid or osteocalcin expression (data not shown).
G-CSF and CYP reduce osteomacs numbers on trabecular bones and frequency of CD11b
þ F4/80 þ Ly-6G þ BM macrophages, whereas AMD3100 does not alter BM macrophage distribution We have previously reported that G-CSF causes a loss of osteoblast-supportive F4/80 þ osteomacs that parallels the loss of endosteal osteoblasts, and that vivo phagocyte depletion results in loss of endosteal osteoblasts, endosteal osteomacs and CD11b þ F4/80 þ Ly-6G þ macrophages in the BM, downregulation of HSC-supportive chemokine and cytokine mRNA transcribed at endosteum and concomitant mobilization of HSC and HPC into the blood. 13, 14 Similarly, specific depletion of CD169 þ macrophages is sufficient to downregulate HSC-supportive chemokines and cytokines in niches and induce HSC mobilization. 21 These congruent observations suggest that osteomacs and/or CD11b þ F4/80 þ Ly-6G þ BM macrophages are pivotal to maintain osteoblasts and HSC niches within the BM. Herein, we find a biphasic response of osteomacs and osteoblasts to CYP. At day 3 post-administration during myelosuppression, the F4/80 þ osteomac layer was thickened to 2 --3 cells instead of the monolayer observed in saline controls ( Figure 3 ) consistent with increased ObS/BS observed at this time-point (Figure 1b) . In the BM, F4/80 þ macrophages were numerous and stellate, indicating active phagocytosis of cell debris resulting from the acute cytotoxicity of CYP on proliferating HPC. Between days 6 --9 when HSPC are mobilized into the blood, osteomacs were depleted from endosteal surfaces in the femoral metaphysis (Figure 3a) in accordance with the loss of osteoblasts observed in this region of the tibia (Figures 1b-e) . Unexpectedly, osteoblasts were still present on endocortical diaphyseal surfaces (Figure 3 ). However, their morphology was abnormally flattened, suggesting deficient bone-forming activity.
CD11b
þ F4/80 þ Ly-6G þ macrophages in the BM were measured by flow cytometry. G-CSF significantly decreased CD11b þ F4/80 þ Ly-6G þ macrophages 24 h after initiation of treatment (Figure 4 ), in parallel with the decrease in endosteal osteoblasts previously reported. 13 In CYP-treated mice, the femur content in CD11b þ F4/80 þ Ly-6G þ macrophages dropped dramatically at day 3 coinciding with BM myeloablation. This decrease was in part due to an 86% reduction of BM cellularity from 25 Â 10 6 leukocytes/femur to 3.4 Â 10 6 leukocytes/femur. Between days 6 --10, the number of BM CD11b þ F4/80 þ Ly-6G þ macrophages was partially restored but remained significantly lower than controls (Figure 4) . In sharp contrast to G-CSF and CYP, AMD3100 did not alter the distribution of F4/80 þ osteomacs at the endosteum (Figure 3 ) nor the number of CD11b þ F4/80 þ Ly-6G þ macrophages in the BM (Figure 4) .
Effect of mobilizing agents on chemokines and cytokines expressed at the endosteum Expression of mRNA encoding CXCL12, KL and angiopoietin-1 in endosteal cells was significantly reduced during G-CSF administration and returned to baseline levels 4 days after cessation of G-CSF ( Figure 5) .
CYP administration caused a 24-fold downregulation in endosteal CXCL12 mRNA expression at the peak of mobilization (day 6), a more pronounced downregulation than the 4-fold reduction observed in response to G-CSF (Figure 6 ). Angiopoietin-1 was also reduced 2.8-fold throughout mobilization between days 6 --8 after CYP, similar to G-CSF treatment. In contrast to G-CSF, however, KL expression was not significantly altered. This suggests that although CXCL12 expression is downregulated in response to CYP and promotes HSPC mobilization, niche functions are not completely impaired and maintenance of KL expression in the BM may support the rapid hematopoietic recovery observed from day 3 onward. AMD3100, while effective at mobilizing after 1 h, did not alter expression of CXCL12, KL or angiopoietin-1 at the endosteum ( Figure 5) . Similarly, a 6-day continuous infusion of AMD3100 did not alter the expression of these cytokines (data not shown).
G-CSF and CYP impair repopulating potential of the mobilized BM As both G-CSF and CYP inhibit osteoblasts and reduce HSC niche function as measured by expression of CXCL12 and angiopoietin-1, we hypothesized that this inhibition of niche function impairs the repopulation potential of HSC remaining in the mobilized BM. To test this, BM cells extracted at the peak of mobilization with G-CSF (day 5), CYP (day 6) and AMD3100 (1 h) were tested in a long-term competitive repopulation assay and compared with that of BM cells from salinetreated mice. Figure 6 shows significantly reduced donor chimerism with BM cells from mice mobilized for 5 days with G-CSF or 6 days after CYP. This corresponded to a 29-fold and 11.9-fold decrease in the number of repopulating units per 200 000 BM cells, respectively. . Effect of mobilizing agents on expression of CXCL12, kit ligand and angiopoietin-1 mRNA at the endosteum. RNA from femoral endosteum was extracted at indicated time points and mRNA levels measured by RT-qPCR using b2-microglogulin primers to standardize results. Each symbol represents an individual mouse. Bars are means of each group. *Po0.05, **Po0.01, ***Po0.001, n.s. is for not significant. Grey boxes on kinetics show time period during which HSPC were mobilized into the blood.
In sharp contrast, the reconstitution potential of BM cells was unaltered after a 1 h AMD3100 treatment, a result in agreement with the absence of effect of AMD3100 on osteoblasts, osteomacs or HSC niche function.
DISCUSSION
As observed with G-CSF, CYP induced a marked reduction in endosteal osteoblasts, bone formation and F4/80 þ osteomacs. Unexpectedly osteoid remained on the endosteum of CYP-treated mice, despite the absence of osteoblasts. The presence of osteoid without osteoblasts is highly unusual, and we have found no reports of this in the published literature. It suggests that osteoblasts were either destroyed or removed while still in the process of actively forming bone. This indicates that, at least in CYP-treated animals, the osteoid is not automatically destroyed when the protective layer of osteoblasts or bone lining cells is absent. Persisting osteoid could be the result of increased osteoblast numbers and function in the first 3 days following administration of CYP. This is also consistent with the thickening of the osteomac canopy at day 3 of CYP. Increased osteoblast activity has also been reported at day 3 of CYP þ G-CSF combination and has been suggested as a cause of increased HSPC mobilization in response to this combination regimen. 30 Our data show that a similar phenomenon occurs in response to CYP alone without G-CSF.
We also observed the persistence of flattened osteocalcinpositive osteoblasts on diaphyseal endocortical surfaces despite the absence of the usual canopy of osteomacs at days 6 --9 following CYP administration. This was unexpected and indicated that osteoblast suppression in response to CYP is zone specific with different outcomes in diaphysis and metaphysis, and that osteoblasts can remain on endocortical surfaces even in the absence of osteomacs, albeit with an unusual flattened morphology that may reflect their poor ability to form bone. This zonespecific effect is unlikely to be due to differential CYP biodistribution or vascularization, as the entire BM tissue is severely damaged in the first 3 days following CYP administration. Therefore, at least in the metaphyseal spongiosa, the effect of CYP and G-CSF are similar with loss of osteomacs, osteoblasts, transient arrest in bone formation and reduced CXCL12 expression. The maintenance of flattened endosteal osteoblasts in the absence of detectable osteomacs in the diaphysis of CYP-treated animals remains puzzling.
In a previous report, we have found that CXCL12 protein is cleaved by neutrophil proteases that accumulate in the BM fluid after 6 --8 days of CYP administration, similar to neutrophil protease accumulation during G-CSF administration. 6 Of note, these previous studies were performed in the BALB/c strain that releases large amounts of neutrophil proteases in the BM in response to G-CSF or CYP 6, 7 The current study was performed in the C57BL/6 strain, which unlike BALB/c, does not release much proteases in response to G-CSF or CYP. Therefore, our results show that the downregulation of CXCL12 in response to CYP is mediated both at the transcriptional level as well as by proteolytic cleavage of the protein, similar to what we have previously found for G-CSF. 6, 10, 14, 15, 31 The more pronounced CXCL12 transcriptional downregulation induced by CYP may explain why a single dose of CYP is more effective to mobilize HSPC than G-CSF.
In addition to osteomacs, BM CD169 þ macrophages are required to maintain the HSC-supportive function of perivascular MSC. 21 We have found that CD11b þ F4/80 þ Ly-6G þ macrophages, which are also CD169 þ (Jacobsen R and Lé vesque JP, unpublished data), are reduced in CYP-mobilized BM. However, we could not investigate whether CYP inhibits the HSC-supportive function of perivascular nestin-positive MSC. The precise effect of CYP on MSC functions remains to be determined. Nevertheless, it is clear that unlike G-CSF, CYP does not completely switch off hematopoietic niche functions as it does not downregulate KL expression and niches in CYP-treated mice can still support hematopoiesis to rapidly restore BM and blood cellularity after the BM aplasia and blood pan-leukopenia that immediately follows CYP administration. However, despite the rapid recovery of HSC and hematopoiesis following the myeloablative phase, CYP impaired osteoblastic niches for quiescent HSC as indicated by (1) the downregulation of angiopoietin-1, which maintains HSC in quiescence 32 and (2) the 11.9-fold reduction in the number of repopulating units present in the BM at the peak of mobilization induced by CYP. Whether this decrease in the repopulation potential of BM mobilized by G-CSF or CYP is solely due to a decrease in HSC niche function, or also in part due to the egress of these repopulating HSC from the BM, or a reduced ability of these mobilized BM HSC to home to the recipient BM remains to be determined.
Finally, AMD3100 had very little effect on osteoblast distribution and morphology, osteomac distribution, and production of HSC-supportive cytokines and chemokines after 1 h administration or even after a 6-day continuous infusion. AMD3100 did not impair the ability of the mobilized BM to competitively repopulate lethally irradiated recipients, suggesting that AMD3100 had no detrimental effect on HSC niches. In conclusion, although G-CSF, CYP and AMD3100 efficiently mobilize HSPC into the blood, the effect of these three drugs on HSC niches, bone formation and repopulation potential of the mobilized BM are distinct. G-CSF and CYP both mobilize by impairing HSC niche function in the BM, whereas AMD3100 directly targets HSC without impairing niche function.
